[go: up one dir, main page]

BR112015011400A2 - composto, composição farmacêutica, composição de vacina, e, uso de um composto - Google Patents

composto, composição farmacêutica, composição de vacina, e, uso de um composto

Info

Publication number
BR112015011400A2
BR112015011400A2 BR112015011400A BR112015011400A BR112015011400A2 BR 112015011400 A2 BR112015011400 A2 BR 112015011400A2 BR 112015011400 A BR112015011400 A BR 112015011400A BR 112015011400 A BR112015011400 A BR 112015011400A BR 112015011400 A2 BR112015011400 A2 BR 112015011400A2
Authority
BR
Brazil
Prior art keywords
compound
integer
alkyl
value
composition
Prior art date
Application number
BR112015011400A
Other languages
English (en)
Other versions
BR112015011400A8 (pt
Inventor
Mary Coe Diane
Allan Smith Stephen
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112015011400A2 publication Critical patent/BR112015011400A2/pt
Publication of BR112015011400A8 publication Critical patent/BR112015011400A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, composiã‡ãƒo de vacina, e, uso de um composto” compostos da fã³rmula (i) e seus sais: em que r1 ã© n-alquila c4-6 ou alcã³xi c1-2 alquila c1-2; r2 ã© hidrogãªnio ou metila; cada r3 ã© hidrã³xi, halo ou n-alquila c1-3; m ã© um nãºmero inteiro tendo um valor de 2 a 4; n ã© um nãºmero inteiro tendo um valor de 0 a 3 e p ã© um nãºmero inteiro tendo um valor de 0 a 2, sã£o indutores de interferon humano. os compostos que induzem o interferon humano podem ser ãºteis no tratamento de vã¡rios distãºrbios, por exemplo, o tratamento de doenã§as alã©rgicas e outras condiã§ãµes inflamatã³rias, por exemplo, rinite alã©rgica e asma, doenã§as infecciosas e cã¢ncer e tambã©m podem ser ãºteis como adjuvantes de vacina.
BR112015011400A 2012-11-20 2013-11-18 composto, composição farmacêutica, composição de vacina, e, uso de um composto BR112015011400A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728390P 2012-11-20 2012-11-20
US201361774087P 2013-03-07 2013-03-07
PCT/US2013/070472 WO2014081645A1 (en) 2012-11-20 2013-11-18 Novel compounds

Publications (2)

Publication Number Publication Date
BR112015011400A2 true BR112015011400A2 (pt) 2017-07-11
BR112015011400A8 BR112015011400A8 (pt) 2019-10-01

Family

ID=50776485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011400A BR112015011400A8 (pt) 2012-11-20 2013-11-18 composto, composição farmacêutica, composição de vacina, e, uso de um composto

Country Status (32)

Country Link
US (3) US9540383B2 (pt)
EP (1) EP2922549B1 (pt)
JP (1) JP6228223B2 (pt)
KR (1) KR20150085055A (pt)
CN (1) CN104780922B (pt)
AU (1) AU2013348218B2 (pt)
BR (1) BR112015011400A8 (pt)
CA (1) CA2892218A1 (pt)
CL (1) CL2015001342A1 (pt)
CR (1) CR20150268A (pt)
CY (1) CY1119557T1 (pt)
DK (1) DK2922549T3 (pt)
DO (1) DOP2015000121A (pt)
EA (1) EA028480B1 (pt)
ES (1) ES2639789T3 (pt)
HR (1) HRP20171150T1 (pt)
HU (1) HUE13857477T2 (pt)
IL (1) IL238800B (pt)
LT (1) LT2922549T (pt)
ME (1) ME02867B (pt)
MX (1) MX358025B (pt)
NZ (1) NZ707319A (pt)
PE (1) PE20151086A1 (pt)
PH (1) PH12015501100B1 (pt)
PL (1) PL2922549T3 (pt)
PT (1) PT2922549T (pt)
RS (1) RS56233B1 (pt)
SG (1) SG11201503282RA (pt)
SI (1) SI2922549T1 (pt)
SM (1) SMT201700378T1 (pt)
UA (1) UA114645C2 (pt)
WO (1) WO2014081645A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
PT2734186T (pt) 2011-07-22 2018-12-17 Glaxosmithkline Llc Composição
PE20150730A1 (es) 2012-08-24 2015-06-02 Glaxosmithkline Llc Compuestos de pirazolopirimidina
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
SG11201503282RA (en) 2012-11-20 2015-06-29 Glaxosmithkline Llc Novel compounds
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
RU2676684C2 (ru) * 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
HUE054672T2 (hu) * 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
TWI558709B (zh) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
CN108349982B (zh) 2015-11-05 2020-05-05 正大天晴药业集团股份有限公司 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
TWI306859B (en) 2000-04-28 2009-03-01 Acadia Pharm Inc Muscarinic agonists
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
DK1348707T3 (da) 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
CN1653077A (zh) * 2002-05-06 2005-08-10 健亚生物科技公司 治疗c型肝炎病毒感染的核苷衍生物
US6713241B2 (en) 2002-08-09 2004-03-30 Eastman Kodak Company Thermally developable emulsions and imaging materials containing binder mixture
ATE505474T1 (de) 2002-08-21 2011-04-15 Einstein Coll Med Inhibitoren von nukleosidphosphorylasen und nukleosidasen
WO2004029054A1 (ja) 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Company, Limited 新規アデニン化合物及びその用途
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
KR20060096415A (ko) 2003-09-05 2006-09-11 애나디스 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스에 의한 감염증을 치료하기 위해투여하는 ｔｌｒ７ 리간드 및 이의 전구약물
UY28506A1 (es) 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
CN1960993A (zh) 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
CA2615946A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
US20090324551A1 (en) 2005-08-22 2009-12-31 The Regents Of The University Of California Office Of Technology Transfer Tlr agonists
KR20080039982A (ko) 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
EP1924581A1 (en) 2005-09-02 2008-05-28 Pfizer, Inc. Hydroxy substituted 1h-imidazopyridines and methods
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20080269240A1 (en) 2005-09-22 2008-10-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel Adenine Compound
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW COMPOUND OF ADENINE
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
CA2680789C (en) 2006-03-28 2016-02-16 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
GB2438679A (en) 2006-05-31 2007-12-05 Sra Dev Ltd Ultrasonic surgical tool having two modes of vibration
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
HRP20110115T1 (hr) 2007-02-19 2011-03-31 Glaxosmithkline Llc Derivati purina kao imunomodulatori
US8063051B2 (en) 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
JP5480637B2 (ja) * 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
KR101561710B1 (ko) 2007-06-29 2015-10-19 길리애드 사이언시즈, 인코포레이티드 퓨린 유도체 및 그것의 톨 유사 수용체 7의 조절 인자로서 용도
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
CN102203095A (zh) 2008-08-11 2011-09-28 葛兰素史密丝克莱恩有限责任公司 用于治疗变应性疾病、炎性疾病和感染性疾病的嘌呤衍生物
EP2320905B1 (en) 2008-08-11 2017-06-28 Glaxosmithkline LLC Novel adenine derivatives
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
JP5519670B2 (ja) 2008-08-11 2014-06-11 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010083725A1 (zh) 2009-01-20 2010-07-29 山东轩竹医药科技有限公司 含有取代的含氮稠杂环的头孢菌素衍生物
JP5861243B2 (ja) * 2009-07-17 2016-02-16 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ５’−メチルチオアデノシンホスホリラーゼ及びヌクレオシダーゼの３−ヒドロキシピロリジン阻害剤
SG178237A1 (en) * 2009-08-07 2012-03-29 Glaxosmithkline Biolog Sa Lipidated oxoadenine derivatives
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
JP5922587B2 (ja) 2010-02-10 2016-05-24 グラクソスミスクライン エルエルシー ６−アミノ−２−｛［（１ｓ）−１−メチルブチル］オキシ｝−９−［５−（１−ピペリジニル）ペンチル］−７，９−ジヒドロ−８ｈ−プリン−８−オンマレイン酸塩
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012106522A2 (en) 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
CA2837207A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
PT2734186T (pt) 2011-07-22 2018-12-17 Glaxosmithkline Llc Composição
PE20150730A1 (es) 2012-08-24 2015-06-02 Glaxosmithkline Llc Compuestos de pirazolopirimidina
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
SG11201503282RA (en) 2012-11-20 2015-06-29 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
RU2676684C2 (ru) 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА

Also Published As

Publication number Publication date
ME02867B (me) 2018-04-20
AU2013348218A1 (en) 2015-06-04
CN104780922A (zh) 2015-07-15
SMT201700378T1 (it) 2017-09-07
US20170080085A1 (en) 2017-03-23
HUE13857477T2 (hu) 2018-05-28
CY1119557T1 (el) 2018-03-07
WO2014081645A1 (en) 2014-05-30
SG11201503282RA (en) 2015-06-29
BR112015011400A8 (pt) 2019-10-01
SI2922549T1 (sl) 2017-10-30
EP2922549A4 (en) 2016-04-06
PT2922549T (pt) 2017-09-01
CN104780922B (zh) 2016-09-07
US20180140695A1 (en) 2018-05-24
HRP20171150T1 (hr) 2017-10-06
IL238800B (en) 2018-10-31
US20150284396A1 (en) 2015-10-08
DOP2015000121A (es) 2015-11-30
CR20150268A (es) 2015-07-01
NZ707319A (en) 2019-09-27
US9907847B2 (en) 2018-03-06
EA028480B1 (ru) 2017-11-30
PH12015501100A1 (en) 2015-07-27
AU2013348218B2 (en) 2016-10-13
UA114645C2 (uk) 2017-07-10
EA201590684A1 (ru) 2016-03-31
JP6228223B2 (ja) 2017-11-08
EP2922549B1 (en) 2017-06-21
CL2015001342A1 (es) 2015-10-02
EP2922549A1 (en) 2015-09-30
IL238800A0 (en) 2015-06-30
KR20150085055A (ko) 2015-07-22
DK2922549T3 (en) 2017-09-11
PE20151086A1 (es) 2015-08-20
PL2922549T3 (pl) 2017-11-30
ES2639789T3 (es) 2017-10-30
CA2892218A1 (en) 2014-05-30
HK1208826A1 (en) 2016-03-18
JP2016500068A (ja) 2016-01-07
LT2922549T (lt) 2017-09-11
US9540383B2 (en) 2017-01-10
PH12015501100B1 (en) 2017-10-06
RS56233B1 (sr) 2017-11-30
MX2015006375A (es) 2015-10-05
MX358025B (es) 2018-08-02

Similar Documents

Publication Publication Date Title
BR112015011400A8 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
BR112015011447A2 (pt) composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
BR112015011439A2 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
BR112014026703A2 (pt) inibidores de dna-pk
EA201590189A1 (ru) Пиразолопиримидиновые соединения
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112014007694A2 (pt) 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)óxi)naftaleno-1-il)ureias como inibidores de p38 map cinase
EA201290631A1 (ru) Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
EA201100113A1 (ru) Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
ME01604B (me) Inhibitori p38 map kinaze
BR112014029185A2 (pt) nucleosídeos de spirooxetano uracila
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112013009395A2 (pt) derivados de quinazolin-4 (3h)-ona usados como inibidores da pi3 cinase
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112014001801A2 (pt) indazóis
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
BRPI0807749B8 (pt) composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos
BR112012027803A2 (pt) compostos de pirazol como inibidores de jak
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements